Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

• Published in: Haematologica (Roma) Vol. 107; no. 3; pp. 625 - 634
• Main Authors: Benjamini, Ohad, Rokach, Lior, Itchaki, Gilad, Braester, Andrei, Shvidel, Lev, Goldschmidt, Neta, Shapira, Shirley, Dally, Najib, Avigdor, Abraham, Rahav, Galia, Lustig, Yaniv, Ben David, Shirley Shapiro, Fineman, Riva, Paz, Alona, Bairey, Osnat, Polliack, Aaron, Levy, Ilana, Tadmor, Tamar
• Format: Journal Article
• Language: English
• Published: Italy Fondazione Ferrata Storti 01.03.2022; Ferrata Storti Foundation
• Subjects: Antibodies, Viral; BNT162 Vaccine; COVID-19 - prevention & control; COVID-19 Vaccines - adverse effects; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; RNA, Messenger - genetics; SARS-CoV-2
• ISSN: 0390-6078; 1592-8721; 1592-8721
• DOI: 10.3324/haematol.2021.279196

Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to vaccination. Recently, BNT162b2, an mRNA COVID-19 vaccine with a high efficacy of 95% in immunocompetent individuals, was introduced. We investigated the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with CLL from nine medical centers in Israel, Overall 400 patients were included, of whom 373 were found to be eligible for the analysis of antibody response. The vaccine appeared to be safe and only grade 1-2 adverse events were seen in 50% of the patients. Following the second dose, an antibody response was detected in 43% of the cohort. Among these CLL patients, 61% of the treatment-na ve patients responded to the vaccine, while responses developed in only 18% of those with ongoing disease, 37% of those previously treated with a BTK inhibitor and 5% of those recently given an anti-CD20 antibody. Among patients treated with BCL2 as monotherapy or in combination with anti-CD20, 62% and 14%, respectively, developed an immune response. There was a high concordance between neutralizing antibodies and positive serological response to spike protein. Based on our findings we developed a simple seven-factor score including timing of any treatment with anti-CD20, age, treatment status, and IgG, IgA, IgM and hemoglobin levels. The sum of all the above parameters can serve as a possible estimate to predict whether a given CLL patient will develop sufficient antibodies. In conclusion, the BNT162b2 mRNA COVID-19 vaccine was found to be safe in patients with CLL, but its efficacy is limited, particularly in treated patients.